Overview
MPLT market data
Price History
MPLT price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for MPLT. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
UBS Maintains Buy on MapLight Therapeutics, Raises Price Target to $52Benzinga · Jul 21, 2026, 6:32 PM
BMO Capital Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $46Benzinga · Jul 21, 2026, 10:03 AM
Craig-Hallum Maintains Buy on MapLight Therapeutics, Lowers Price Target to $40Benzinga · Jun 23, 2026, 1:15 PM
Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $42Benzinga · Jun 22, 2026, 5:30 PM
MapLight Therapeutics Autism Drug Shows Mixed Potential In AdolescentsBenzinga · Jun 22, 2026, 5:30 PM
MapLight Therapeutics Announces Topline Results From Its IRIS A Phase 2 Study Of ML-004 In Autism Spectrum Disorder; Trial Did Not Meet Its Primary Endpoint In Social Communication Deficits Associated With Autism Spectrum DisorderBenzinga · Jun 22, 2026, 11:10 AM
8-K filing — MapLight Therapeutics, Inc. (MPLT)SEC EDGAR · Jun 22, 2026, 11:08 AM
MapLight Therapeutics' Vishwas Setia Separated As CFO Effective Immediately; Jonathan Gillis Appointed As Interim CFO Effective June 18, 2026Benzinga · Jun 18, 2026, 9:10 PM
Stifel Maintains Buy on MapLight Therapeutics, Raises Price Target to $36Benzinga · Jun 2, 2026, 2:27 PM
HC Wainwright & Co. Reiterates Buy on MapLight Therapeutics, Maintains $45 Price TargetBenzinga · May 28, 2026, 12:30 PM